With our advanced biomarker detection and molecular profiling, we go beyond standard protocols. We provide the medical team with accurate information to design a fully targeted therapeutic strategy, ensuring that each patient receives the most effective and humane approach.
All liquid biopsy tests require two tubes of blood and are performed using next-generation sequencing (NGS) techniques.
OncoProfile Liquid General 52 is capable of evaluating 52 genes with proven clinical utility in cell-free tumor DNA (ctDNA), including key targets recognized by experts (SNVs, InDels, CNVs, and gene fusions).
OncoProfile Liquid General 52 is capable of evaluating 52 genes with proven clinical utility in cell-free tumor DNA (ctDNA), including key targets recognized by experts (SNVs, InDels, CNVs, and gene fusions).
OncoProfile Liquid Mama 12 Evaluates 12 genes, providing information to identify tumor heterogeneity, sensitivity to therapies, treatment-resistant clones, and recurrence prior to imaging tests.
OncoProfile Liquid Lung 12 analiza 12 genes ofreciendo información relevante para la selección de terapias dirigidas, la detección de resistencias adquiridas y monitorización de recurrencias. Además, presenta un gran valor en el estudio genético, así como complemento diagnóstico en NSCLC.
Between 10 and 15% of cancers are caused by inherited mutations in the germline. Although rare, these mutations significantly increase the risk of developing certain tumors.
Inherit-Gene Cancer Test 39 analyzes 39 genes associated with hereditary cancer syndromes, including known high-penetrance genes (such as BRCA1, BRCA2, PALB2, TP53, PTEN, CDH1, STK11), to identify pathogenic variants linked to an increased risk of multiple types of cancer.
Inherit-Gene Cancer Test 200+ analyzes more than 200 genes associated with hereditary cancer syndromes, including high-penetrance genes (such as BRCA1, BRCA2, PALB2, TP53, PTEN, or CDH1), offering a comprehensive assessment of genetic risk for multiple types of cancer.
Using an innovative and sophisticated methodology, we culture tumor cells from the patient and treat them with different drugs, allowing us to accurately predict the clinical response.
It analyzes, in a single assay, more than 500 genes to provide a comprehensive genomic profile that includes TMB, MSI, SNVs, indels, CNVs, and gene fusions, supporting personalized precision-therapy decisions.
Our pharmacogenomic tests identify variants that affect the metabolism of high-impact chemotherapy drugs, allowing the oncologist to adjust individualized treatments before toxicity occurs; they are based on polymorphisms with validated clinical relevance.
DETEKTION GENOMISCHER INSTABILITÄT
We identify markers of genomic instability, such as microsatellite instability (MSI) and tumor mutational burden (TMB), which reflect the tumor’s ability to mutate and evolve.
SPECIFIC MUTATION DETECTION
Thanks to our real-time and digital PCR technologies, along with other molecular methodologies, we offer highly sensitive and specific detection of point mutations across a variety of cancer types.
© Oncodynamics
Diseño web: Maddon Advertising S.L.
